About Genopole®

Genopole® is France’s leading biotech- and biotherapy-dedicated science and business park

The Genopole® project was initiated in 1998 in the town of Evry-Corbeil (in the Essonne county, just south of Paris), under the impetus of the French government, Ile-de-France Regional Council, Essonne County Council and the French Muscular Dystrophy Association (Association Française contre les Myopathies, AFM); the goal was to create France’s first ever science and business park dedicated to genomics, genetics and biotech and help the country to catch up with its international rivals in these fields.

By modeling itself on world-class North American and European bioclusters, Genopole® has pioneered this approach in France.

In addition to constant support from its founding members and other partners, Genopole®’s success is largely based on the novelty of its approach: bringing together public- and private-sector research labs, university teaching facilities and life science start-ups on a single campus in Evry–Corbeil.

Key-figures

66 biotech companies
20 academic research labs
17 shared-access technology platforms and technical facilities
86,538 m2 of real estate
€272,25 million in equity funding raised by Genopole® companies
942 patents filed by campus companies
26 molecules or biotherapies in development or on the market, from the regulatory preclinical phase through to market launch
2 186 direct jobs

From the outset, Genopole® has striven to offer researchers and entrepreneurs the skills and the scientific & business environment that they need in order to succeed. Genopole® has dedicated staff, facilities and resources for meeting its objectives: funding research, promoting therapeutic innovation and transferring technology to industry.

With 20 public-sector research laboratories and 66 companies in its portfolio, Genopole® stands out as France’s benchmark biopark; it is contributing to the emergence of French biotech and is helping France position itself in a highly competitive international scientific and industrial environment.

Genopole® - a founding member of the “Medicen Paris Region” world-class healthcare and life science cluster

Genopole®’s rapid growth and novel features now make it a major player on the international stage. This visibility gives Genopole® the ability to respond to strategic, wide-ranging projects such as that embodied by creation of the Medicen Paris Region healthcare and life science cluster.

Medicen Paris Region (accredited in 2005 following a call for tenders by French government) is a world-class cluster that federates companies, national research institutes and local authorities around a common goal: reinforcing the competitiveness, visibility and attractiveness of Paris and its region in the life science, medtech and pharmaceutical sectors.

Constitution of this vast cluster will enable the Paris Ile-de-France region to assert itself by 2010 as Europe’s leading industrial center for drug and therapeutic innovation and a world-leading biotech cluster.

Medicen Paris Region has 6 high-priority themes: neuroscience, oncology, infectious disease, biomedical imaging, molecular & cellular medicine and drug science & technology.

President: David Sourdive

Vice Presidents: Thierry Damerval (Research), Dominique Franco (Health)
CEO: François Chevillard

[+] Previous page